Newsfeeds - Spark Newswire

2 minute read

Humacyte Presents Preclinical Results Of Small-Diameter HAV For Use As A BTT Shunt In Pediatric Heart Disease At American Heart Association’s Scientific Sessions 2021

Today, 1:31 PM

Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced positive results from a preclinical study

HUMA

1 minute read

Humacyte Q3 EPS $(0.72) Up From $(3.07) YoY, Grant Sales $241.00K Down From $914.00K YoY

By Benzinga Newsdesk

Today, 1:31 PM

Humacyte (NASDAQ:HUMA) reported quarterly losses of $(0.72) per share. This is a 76.55 percent increase over losses of $(3.07) per share from the same period last year. The company reported $241.00 thousand in sales

HUMA

5 minute read

64 Biggest Movers From Yesterday

By Lisa Levin

Today, 1:31 PM

Gainers ABVC BioPharma, Inc. (NASDAQ: ABVC) shares climbed 137.4% to close at $6.03 on Monday on abnormally-high volume. The stock is seeing increased interest by traders on social media. Also, the company filed a mixed shelf offering on Friday after the close.

ABVC

9 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For October 29, 2021

By Benzinga Insights

Today, 1:31 PM

ACVA

1 minute read

Cowen & Co. Initiates Coverage On Humacyte with Outperform Rating, Announces Price Target of $17

By Benzinga Newsdesk

Today, 1:31 PM

Cowen & Co. analyst Joshua Jennings initiates coverage on Humacyte (NASDAQ:HUMA) with a Outperform rating and announces Price Target of $17.

HUMA

11 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For September 24, 2021

By Benzinga Insights

Today, 1:31 PM

Upgrades

ACHC

1 minute read

Oppenheimer Initiates Coverage On Humacyte with Outperform Rating, Announces Price Target of $16

By Benzinga Newsdesk

Today, 1:31 PM

Oppenheimer analyst Suraj Kalia initiates coverage on Humacyte (NASDAQ:HUMA) with a Outperform rating and announces Price Target of $16.

HUMA

1 minute read

BTIG Initiates Coverage On Humacyte with Buy Rating, Announces Price Target of $19

By Benzinga Newsdesk

Today, 1:31 PM

BTIG analyst Ryan Zimmerman initiates coverage on Humacyte (NASDAQ:HUMA) with a Buy rating and announces Price Target of $19.

HUMA

2 minute read

Events
News

Humacyte Highlights List Of Sept. Presentations, Including Upcoming Events On Sept. 17, 23, 24

By Benzinga Newsdesk

Today, 1:31 PM

Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that senior leadership will present at

HUMA

5 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For September 16, 2021

By Benzinga Insights

Today, 1:31 PM

AXP